Predictive factors of histological response to primary chemotherapy in Ewing's sarcoma

Acta Oncologica

Volumn 37, Issue 7-8, 1998, Pages 671-676

  Bacci, Gaetano ^a,c   Picci, Piero ^a   Mercuri, Mario ^a   Ferrari, Stefano ^a   Longhi, Alessandra ^a   Cesari, Marilena ^a   Rosito, Pasquale ^b   Mancini, Antonia F ^b   Barbieri, Enza ^b   Baldini, Nicola ^a  

^a Istituti Ortopedici Rizzoli ^*  (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c Sezione di Chemioterapia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DACTINOMYCIN; IFOSFAMIDE; LACTATE DEHYDROGENASE; VINCRISTINE;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; DATA ANALYSIS; EWING SARCOMA; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; PREDICTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RELIABILITY; TREATMENT OUTCOME; TUMOR VOLUME;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; IFOSFAMIDE; INFANT; MALE; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; SARCOMA, EWING'S; VINCRISTINE;

EID: 0032426499     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/028418698430025     Document Type: Article

References (20)

1. 1. Alvegård TA, Solheim Ø, Åkerman M, Berg NO. Ewing's sarcoma. A preliminary report from the Scandinavian Sarcoma Group. Acta Oncol 1989; 28 (Suppl 2): 59-64.
2. 2. Bacci G, Picci P, Avella M, et al. Neoadjuvant chemotherapy for localized Ewing's sarcoma of bone: experience at the Istituto Ortopedico Rizzoli. Cancer J 1991; 4: 335-42.
3. 3. Craft AW, Cotterill SBA, Imeson J. Improvement in survival for Ewing's sarcoma by substitution of ifosfamide for cyclophosphamide. A UKCCSG/MRC Study. Am J Pediat Hematol Oncol 1993; 15: 31-5.
4. 4. Dunst J, Jürgens H, Sauer R, et al. Radiation therapy in Ewing's sarcoma: an update of the CESS-86 trial. Int J Rad Oncol Biol Phys 1995; 4: 919-30.
5. 5. Elomaa I, Blomqvist C, Sæter G, et al. Three-year results of the SSG IX protocol in Ewing's sarcoma. Acta Orthop Scand 1994; 65: 77-8.
6. 6. Jürgens H, Exner U, Gadner H, et al. Multidisciplinary treatment of primary Ewing's sarcoma of bone. Cancer 1988; 61: 23-32.
7. 7. Oberlin O, Habrand JL, Zucker JM, et al. No benefit of ifofasfamide in Ewing's sarcoma: a nonrandomized study of the French Society of Pediatric Oncology. J Clin Oncol 1992; 10: 1407-12.
8. 8. Oberlin O, Patte C, Deméocq F, et al. The response to initial chemotherapy as a prognostic factor in localized Ewing's sarcoma. Eur J Cancer Clin Oncol 1985; 21: 463-7.
9. 9. Sailer SL, Harmon DC, Mankin HJ, et al. Ewing's sarcoma: surgical resection as prognostic factor. Int J Radiat Oncol Biol Phys 1988; 15: 43-52.
10. 10. Sauer R, Jürgens H, Burgers JMV, et al. Prognostic factors in the treatment of Ewing's sarcoma. Radiother Oncol 1987; 10: 101-10.
11. 11. Åkerman M. Tumour necrosis and prognosis in Ewing's sarcoma. Acta Orthop Scand 1997; 273 (Suppl): 130-2.
12. 12. Ayala AG. Tumor necrosis in treated Ewing's sarcoma. Presented at the 32nd Annual Conference: Optimizing Management of Primary Bone Tumors: An International Symposium Emphasizing the Multi-Disciplinary Approach. Houston, TX, November 25, 1988.
13. 13. Delepine N, Delepine G, Cornille H, et al. Prognostic factors in patients with localized Ewing's sarcoma: the effect on survival of actual received drug dose intensity and of histologic response to chemotherapy. J Chemotherapy 1997; 9: 352-63.
14. 14. Picci P, Böhling T, Bacci G, et al. Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing's sarcoma of the extremities. J Clin Oncol 1997; 15: 1553-9.
15. 15. Jürgens HF. Ewing's sarcoma and peripheral primitive neuroectodermal tumor. Curr Opin Oncol 1994; 6: 391-6.
16. 16. Göbel U, Jürgens H, Etspuler G, et al. The prognostic significance of tumor volume in localized Ewing's sarcoma of bone in children and adolescents. J Cancer Res Clin Oncol 1987; 113: 187-93.
17. 17. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of muscoloskeletal sarcoma. Clin Orthop 1980; 153: 116-20.
18. 18. Jürgens H, Exner U, Kuhl J, et al. High-dose ifosfamide with mesna uroprotection in Ewing's sarcoma. Cancer Chemother Pharmacol 1989; 24 (Suppl 1): S40-S44.
19. 19. Magrath IT, Sandlund JT, et al. A phase II study of ifosfamide in the treatment of recurrent sarcomas in pediatric tumors. Contr Oncol 1987; 26: 114-24.
20. 20. Miser JS, Kinsella TJ, Triche TJ, et al. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol 1987; 5: 1191-8.